Racial differences in primary cytogenetic abnormalities in multiple myeloma: a multi-center study

被引:17
|
作者
Greenberg, A. J. [1 ]
Philip, S. [2 ]
Paner, A. [3 ]
Velinova, S. [4 ]
Badros, A. [2 ]
Catchatourian, R. [4 ]
Ketterling, R. [1 ]
Kyle, R. A. [1 ]
Kumar, S. [1 ]
Vachon, C. M. [1 ]
Rajkumar, S. V. [1 ]
机构
[1] Mayo Clin, Dept Med, Div Hematol, 200 First St SW, Rochester, MN 55906 USA
[2] Univ Maryland, Baltimore, MD 21201 USA
[3] Rush Univ, Med Ctr, Chicago, IL 60612 USA
[4] Cook Cty Hosp, Div Hematol & Oncol, Chicago, IL 60612 USA
来源
BLOOD CANCER JOURNAL | 2015年 / 5卷
关键词
D O I
10.1038/bcj.2014.91
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We examined four clinically assessed cytogenetic subtypes (t(11; 14), t(4; 14), monosomy 13/del13q and monosomy 17/del17p in 292 black patients with newly diagnosed multiple myeloma (MM) from four medical centers, who had fluorescent in situ hybridization testing results available in their medical records. We then compared the prevalence of these abnormalities with a previously characterized Mayo Clinic cohort of 471 patients with MM. We found a significant difference in the prevalence of the t(11; 14) immunoglobulin heavy chain (IgH) translocation between blacks and whites, 6.5% versus 17.6%, respectively, P<0.0001. Blacks also had lower rates of the t(4; 14) IgH translocation, (5.5% versus 10%); monosomy 13/del13q (29.1 versus 49.3%); and monosomy 17/del17p (7.9% versus 13%). Consequently, 63.4% of blacks versus 34.6% of whites did not have any of the four abnormalities that we studied, P<0.001. As almost all MM is associated with either an IgH translocation or trisomies, we hypothesize that MM in blacks is associated with either excess prevalence of either the trisomic (hyperdiploid) form of MM or an IgH translocation besides t(11; 14) or t (4; 14). We conclude that there are significant differences in the cytogenetic subtypes of MM that occur in blacks and whites.
引用
收藏
页码:e271 / e271
页数:4
相关论文
共 50 条
  • [41] Multiple primary malignant neoplasms: Multi-center results from Turkey
    Babacan, N. A.
    Aksoy, S.
    Cetin, B.
    Ozdemir, N. Y.
    Benekli, M.
    Uyeturk, U.
    Kaplan, M. Ali
    Kos, T.
    Karaca, H.
    Oksuzoglu, B.
    Zengin, N.
    Buyukberber, S.
    JOURNAL OF BUON, 2012, 17 (04): : 770 - 775
  • [42] Clinical Outcome of Induction Treatment in the Era of Novel Agents and the Impact of the Number of High-Risk Cytogenetic Abnormalities (HRA) on Prognosis of Patients with Newly Diagnosed Multiple Myeloma (NDMM): Insights from a Multi-Center Study
    Liang, Dong
    Feng, Demei
    Wang, Qiaoli
    Bai, Shenrui
    Zeng, Min
    Lu, Bo
    Li, Xiaoqing
    Sun, Zhiqiang
    Li, Jianyun
    Zhou, Huanhuan
    Zhang, Jialu
    Chen, Xiaoqin
    Xia, Zhongjun
    Liang, Yang
    Wang, Hua
    BLOOD, 2024, 144 : 7064 - 7065
  • [43] Racial differences and cytogenetic abnormalities in hematologic malignancies: A 5-year retrospective study.
    Cheng, LR
    Ramesh, KH
    Burns, ER
    Park, JC
    Cannizzaro, LA
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2000, 114 (04) : 649 - 650
  • [44] CYTOGENETIC STUDY IN MULTIPLE-MYELOMA
    FERTI, A
    PANANI, A
    ARAPAKIS, G
    RAPTIS, S
    CANCER GENETICS AND CYTOGENETICS, 1984, 12 (03) : 247 - 253
  • [45] Importance of cytogenetic study in multiple myeloma
    Pinto-Leite, Rosario
    Souto, Marta
    Botelho, Pedro
    Cunha, Manuel
    Moutinho, Osvaldo
    Martins, Marcia
    MEDICINE, 2016, 95 (10)
  • [46] The prognostic value of the MASS in a multi-center cohort of patients with newly diagnosed multiple myeloma
    Peiyu Yang
    Fan Zhou
    Yujun Dong
    Guangxun Gao
    Hua Xue
    Xinyue Liang
    Shanshan Yu
    Weiling Xu
    Yanping Ma
    Xiaoqi Qin
    Mengyao Li
    Yun Dai
    Fengyan Jin
    Blood Cancer Journal, 12
  • [47] Evidence of decreased prevalence of the t(11;14) translocation in black patients with multiple myeloma: A multi-center study
    Greenberg, Alexandra Joelle
    Philip, Sunita
    Paner, Agne
    Velinova, Sylvia
    Badros, Ashraf
    Catchatorian, Rosalind
    Larson, Dirk
    Ketterling, Rhett
    Kyle, Robert A.
    Kumar, Shaji
    Vachon, Celine M.
    Rajkumar, S. Vincent
    CANCER RESEARCH, 2014, 74 (19)
  • [48] The prognostic value of the MASS in a multi-center cohort of patients with newly diagnosed multiple myeloma
    Yang, Peiyu
    Zhou, Fan
    Dong, Yujun
    Gao, Guangxun
    Xue, Hua
    Liang, Xinyue
    Yu, Shanshan
    Xu, Weiling
    Ma, Yanping
    Qin, Xiaoqi
    Li, Mengyao
    Dai, Yun
    Jin, Fengyan
    BLOOD CANCER JOURNAL, 2022, 12 (09)
  • [49] A prospective multi-center trial of non-in-terventional and observational study of lenalidomide in Chinese patients with multiple myeloma
    王国苗
    China Medical Abstracts(Internal Medicine), 2017, 34 (03) : 184 - 185
  • [50] A phase 1, multi-center, dose escalation study of atiprimod in patients with refractory or relapsed multiple myeloma (MM).
    Wang, M
    Talpaz, M
    Jagannath, S
    Chanan-Khan, AA
    Alexanian, R
    Weber, DM
    Gavino, M
    Estrov, Z
    Harris, PJ
    Picker, D
    Schlossman, RL
    Tassone, P
    Anderson, KC
    Munshi, NC
    BLOOD, 2005, 106 (11) : 36A - 37A